A CHOP regimen is effective for post-transplant lymphoproliferative disorders (PTLD) that have progressed after first-line therapy with rituximab

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1588, 2007-01, pp. : 18-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rituximab + CHOP: first-line therapy in B-cell lymphoma

By  

Inpharma, Vol. 1, Iss. 1323, 2002-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Esomeprazole: effective first-line therapy for acid-related disorders

By  

Inpharma, Vol. 1, Iss. 1370, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Iodine-131 tositumomab [Bexxar] is effective in B-cell lymphoma that has progressed after rituximab therapy

By  

Inpharma, Vol. 1, Iss. 1482, 2005-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Post-Transplant Lymphoproliferative Disease: Association with Induction Therapy?

By Dharnidharka Vikas R.  

Drugs, Vol. 66, Iss. 4, 2006-01 ,pp. : 429-438

Adis International

Access to resources Recommend Favorite

Prednisone/tacrolimus: Post-transplant lymphoproliferative disorder in an infant successfully treated with rituximab: case report

By  

Reactions Weekly, Vol. 1, Iss. 1176, 2007-01 ,pp. : 26-26

Adis International

Access to resources Recommend Favorite